A Study of Combined Onabotulinumtoxin A and Hyaluronic Acid Filler for the Treatment of Enlarged Facial Pores.

IF 4 3区 医学 Q2 FOOD SCIENCE & TECHNOLOGY Toxins Pub Date : 2025-01-15 DOI:10.3390/toxins17010038
Vasanop Vachiramon, Sonphet Chirasuthat, Suphagan Boonpethkaew, Nawara Sakpuwadol, Tanat Yongpisarn, Natthachat Jurairattanaporn
{"title":"A Study of Combined Onabotulinumtoxin A and Hyaluronic Acid Filler for the Treatment of Enlarged Facial Pores.","authors":"Vasanop Vachiramon, Sonphet Chirasuthat, Suphagan Boonpethkaew, Nawara Sakpuwadol, Tanat Yongpisarn, Natthachat Jurairattanaporn","doi":"10.3390/toxins17010038","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Enlarged facial pores are a common cosmetic concern caused by excessive sebum production, visible hair shafts, and a reduction in skin elasticity, leading to a decrease in skin quality and overall appearance. Various treatment modalities have been explored to address this issue. This study focuses on the efficacy and safety of combining Onabotulinumtoxin A (OnaBoNT-A) and hyaluronic acid filler (HA filler) to target enlarged facial pores in Asians.</p><p><strong>Materials and methods: </strong>This study aimed to compare the efficacy and safety of OnaBoNT-A monotherapy in combination with HA filler for the treatment of enlarged facial pores. This study was a prospective, randomized, single-blinded, split-face, controlled trial that enrolled 32 subjects with visibly enlarged pores on both cheeks. One side of the face received intradermal injections of OnaBoNT-A, while the other side received OnaBoNT-A in combination with intradermal hyaluronic acid filler injection. The outcomes were measured by pore volume, visual assessment, pain score, improvement score, and side effects at various time intervals up to 24 weeks.</p><p><strong>Results: </strong>This study investigated the effects of onaBoNT-A monotherapy or in combination with HA filler on facial pore size and skin roughness. The results showed that both sides exhibited a reduction in pore volume and skin roughness over time, but the side treated with onaBoNT-A monotherapy had a slightly better improvement than the combination side at the 6-month follow-up. Subjects with histories of facial oiliness were more likely to respond to onaBoNT-A monotherapy, while those without histories of facial oiliness were more likely to respond to the side treated with combined treatment. The most common adverse events were erythema, bruising, and edema, which were more frequent on the combination side. Additionally, 18 subjects (56.25%) experienced a palpable lump on the combination side, which resolved in most cases within a few months.</p><p><strong>Conclusion: </strong>BoNT-A and HA dermal filler had a role in reducing pore size. Nonetheless, individuals with enlarged pores who exhibited beneficial effects to botulinum toxin injection typically had a background of facial oiliness. Adverse incidents like dermal edema and palpable nodules were observed, underscoring the significance of meticulous patient selection and accurate injection technique.</p>","PeriodicalId":23119,"journal":{"name":"Toxins","volume":"17 1","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11768511/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxins","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/toxins17010038","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"FOOD SCIENCE & TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Enlarged facial pores are a common cosmetic concern caused by excessive sebum production, visible hair shafts, and a reduction in skin elasticity, leading to a decrease in skin quality and overall appearance. Various treatment modalities have been explored to address this issue. This study focuses on the efficacy and safety of combining Onabotulinumtoxin A (OnaBoNT-A) and hyaluronic acid filler (HA filler) to target enlarged facial pores in Asians.

Materials and methods: This study aimed to compare the efficacy and safety of OnaBoNT-A monotherapy in combination with HA filler for the treatment of enlarged facial pores. This study was a prospective, randomized, single-blinded, split-face, controlled trial that enrolled 32 subjects with visibly enlarged pores on both cheeks. One side of the face received intradermal injections of OnaBoNT-A, while the other side received OnaBoNT-A in combination with intradermal hyaluronic acid filler injection. The outcomes were measured by pore volume, visual assessment, pain score, improvement score, and side effects at various time intervals up to 24 weeks.

Results: This study investigated the effects of onaBoNT-A monotherapy or in combination with HA filler on facial pore size and skin roughness. The results showed that both sides exhibited a reduction in pore volume and skin roughness over time, but the side treated with onaBoNT-A monotherapy had a slightly better improvement than the combination side at the 6-month follow-up. Subjects with histories of facial oiliness were more likely to respond to onaBoNT-A monotherapy, while those without histories of facial oiliness were more likely to respond to the side treated with combined treatment. The most common adverse events were erythema, bruising, and edema, which were more frequent on the combination side. Additionally, 18 subjects (56.25%) experienced a palpable lump on the combination side, which resolved in most cases within a few months.

Conclusion: BoNT-A and HA dermal filler had a role in reducing pore size. Nonetheless, individuals with enlarged pores who exhibited beneficial effects to botulinum toxin injection typically had a background of facial oiliness. Adverse incidents like dermal edema and palpable nodules were observed, underscoring the significance of meticulous patient selection and accurate injection technique.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肉毒杆菌毒素A与透明质酸复合填充剂治疗面部毛孔粗大的研究。
面部毛孔粗大是一种常见的美容问题,它是由皮脂分泌过多、毛干明显、皮肤弹性降低引起的,从而导致皮肤质量和整体外观下降。已经探索了各种治疗方式来解决这个问题。本研究的重点是onabtulintoxin A (OnaBoNT-A)联合透明质酸填充剂(HA filler)治疗亚洲人面部毛孔粗大的疗效和安全性。材料与方法:本研究旨在比较OnaBoNT-A单药联合HA填充剂治疗面部毛孔粗大的疗效和安全性。这项研究是一项前瞻性、随机、单盲、裂脸、对照试验,招募了32名双颊毛孔明显扩大的受试者。一侧面部皮内注射OnaBoNT-A,另一侧面部皮内注射OnaBoNT-A联合透明质酸填充剂注射。结果通过孔隙体积、视觉评估、疼痛评分、改善评分和副作用在不同的时间间隔内测量,直至24周。结果:本研究探讨了onaBoNT-A单药治疗或与HA填料联合治疗对面部毛孔大小和皮肤粗糙度的影响。结果显示,随着时间的推移,两侧的毛孔体积和皮肤粗糙度都有所减少,但在6个月的随访中,接受onaBoNT-A单药治疗的一侧比联合治疗的一侧有略好的改善。有面部油腻史的受试者更有可能对onaBoNT-A单药治疗产生反应,而没有面部油腻史的受试者更有可能对联合治疗的一侧产生反应。最常见的不良事件是红斑、瘀伤和水肿,这些在联合用药侧更为常见。此外,18名患者(56.25%)在联合侧出现可触及的肿块,大多数病例在几个月内消退。结论:BoNT-A和HA真皮填充剂具有缩小毛孔的作用。尽管如此,那些对肉毒杆菌毒素注射有益的毛孔粗大的人通常有面部油腻的背景。观察到皮肤水肿和可触及结节等不良事件,强调细致的患者选择和准确的注射技术的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Toxins
Toxins TOXICOLOGY-
CiteScore
7.50
自引率
16.70%
发文量
765
审稿时长
16.24 days
期刊介绍: Toxins (ISSN 2072-6651) is an international, peer-reviewed open access journal which provides an advanced forum for studies related to toxins and toxinology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
期刊最新文献
Gut Epithelium of the Highly Toxic Ribbon Worm Cephalothrix cf. simula (Palaeonemertea, Nemertea) Contains Tetrodotoxin-Positive Bacterial Endosymbionts. Therapeutic Effects of Single and Combined Anti-Disseminated Intravascular Coagulation (DIC) Drugs in a Rat Venom-Induced Consumption Coagulopathy (VICC) Model Using Yamakagashi (Rhabdophis tigrinus) Venom. Occurrence, Distribution Characteristics, Risk Assessment, and Climatic Drivers of Type B Trichothecenes and Their Transformation Products in Major Wheat-Producing Areas of China. Human Organoids and Organ-on-Chip for Biotoxin Assessment: Applications, Best Practices, and a Translational Roadmap. Early Use of Botulinum Toxin in Post-Stroke Spasticity Has the Potential to Prevent Post-Stroke Upper Limb Pain-A Secondary Analysis of the EUBoSS Randomised Controlled Trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1